VirX™, also branded as enovid™ in certain countries, is approved as a medical device in Israel, Bahrain, Thailand and received a CE mark in the EU.  It is not yet approved for sale in Canada.

VirXTM and enovidTM nasal therapeutics are identical formulations based on our NORSTM (Nitric Oxide Releasing Solution) platform technology. They have the same active ingredients and mechanisms of action as those used in the UK trial referenced below in “Human Testing Results”.

 

Lab Testing Results

In-vitro studies, done by an external virology lab* confirms the virucidal activity of VirX™/ enovid™.

 

Human Testing Results

In a randomized, double-blind, placebo-controlled Phase 2 trial that evaluated 79 confirmed cases of COVID-19, SaNOtize’s early treatment for COVID-19 significantly reduced the level of SARS-CoV-2, including in patients with high viral loads. The average viral log reduction in the first 24 hours was 1.362, which corresponds to a decline of about 95%. Within 72 hours, the viral load dropped by more than 99%. The majority of these patients had been infected with the UK variant, which is considered a variant of concern.


Data was published at the Journal of Infection:

Web link: Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection

PDF: Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection


* Institute of Antiviral Research, Utah State University, Logan, Utah , USA

logged in